Processa Pharmaceuticals Inc./$PCSA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Ticker
$PCSA
Sector
Primary listing
Employees
10
Headquarters
PCSA Metrics
BasicAdvanced
$8.8M
-
-$16.58
1.09
-
Price and volume
Market cap
$8.8M
Beta
1.09
52-week high
$8.88
52-week low
$3.28
Financial strength
Current ratio
3.762
Quick ratio
3.614
Profitability
EBITDA (TTM)
-13.02
Management effectiveness
Return on assets (TTM)
-129.94%
Return on equity (TTM)
-270.74%
Valuation
Price to book
1.41
Price to tangible book (TTM)
1.41
Price to free cash flow (TTM)
-0.284
Free cash flow yield (TTM)
-352.70%
Free cash flow per share (TTM)
-13.755
Growth
Earnings per share change (TTM)
-85.42%
3-year earnings per share growth (CAGR)
-68.92%
PCSA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Processa Pharmaceuticals Inc. stock?
Processa Pharmaceuticals Inc. (PCSA) has a market cap of $8.8M as of December 19, 2025.
What is the P/E ratio for Processa Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for Processa Pharmaceuticals Inc. (PCSA) stock is 0 as of December 19, 2025.
Does Processa Pharmaceuticals Inc. stock pay dividends?
No, Processa Pharmaceuticals Inc. (PCSA) stock does not pay dividends to its shareholders as of December 19, 2025.
When is the next Processa Pharmaceuticals Inc. dividend payment date?
Processa Pharmaceuticals Inc. (PCSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Processa Pharmaceuticals Inc.?
Processa Pharmaceuticals Inc. (PCSA) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.